Imatinib Beta

Imatinib, the active ingredient in Imatinib Beta, is a tyrosine kinase inhibitor presented as an unspecified strength/oral tablet for oral use. It targets specific cancers such as chronic myeloid leukemia, gastrointestinal stromal tumor, and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Imatinib Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Imatinib Beta is used to treat malignancies driven by abnormal tyrosine‑kinase signaling.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth driven by c‑KIT mutations. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): blocks BCR‑ABL activity to achieve remission.

Imatinib Beta may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: swelling of the hands, feet or ankles. - Muscle cramps: intermittent tightness or pain in skeletal muscles. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Cardiac failure: signs of reduced heart function such as shortness of breath or peripheral edema.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Dose adjustment in renal impairment: assess renal function and consider reduced dosing. - Monitor hepatic function: check liver enzymes regularly during treatment. - Assess for cardiovascular disease: watch for signs of heart failure or reduced ejection fraction. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Pregnancy and lactation: use only if the potential benefit justifies the risk to the fetus or infant. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce imatinib exposure. - Antacids containing aluminum or magnesium: can decrease oral absorption of imatinib. - Concurrent use with other BCR‑ABL inhibitors: increases risk of overlapping toxicities.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and require dose adjustment. - Warfarin: imatinib can enhance anticoagulant effect; monitor INR closely.